Target Snapshot

CHEMBL258 Target Snapshot

Tyrosine-protein kinase Lck · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card

6,849Compounds

1,338Assays

70Approved Drugs

6,809.0Activities

Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Tyrosine-protein kinase Lck shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P06239. Start with chromophobe renal cell carcinoma, then reuse UniProt P06239 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with chromophobe renal cell carcinoma, then reuse UniProt P06239 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug

Open source guide

Disease program

chromophobe renal cell carcinoma

Start review with chromophobe renal cell carcinoma because it currently carries approved-linked support. Linked drugs include PAZOPANIB HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Approved-linked Open Targets-ready proxy 1 linked drug

Open disease block

Protein anchor

Tyrosine-protein kinase Lck

Review this target as Tyrosine-protein kinase Lck, mapped to UniProt P06239. Sequence length is 509 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P06239 Protein 509 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Lck as ChEMBL target CHEMBL258, mapped to UniProt P06239. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Tyrosine-protein kinase Lck

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL258

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P06239

Tyrosine-protein kinase Lck

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase Lck is the right protein anchor across sources, using UniProt P06239 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chromophobe renal cell carcinoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	Tyrosine-protein kinase Lck
Target Type	SINGLE PROTEIN
Organism	Homo sapiens
UniProt	P06239

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	Tyrosine-protein kinase Lck
UniProt Accession	P06239
Component Type	Protein
Sequence Length	509 aa

Tyrosine-protein kinase Lck

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 13, 2026, 7:10 PM KST As of · Sep 13, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as Tyrosine-protein kinase Lck, mapped to UniProt P06239. Sequence length is 509 aa.

Mapped IDP06239

Review nameTyrosine-protein kinase Lck

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Tyrosine-protein kinase Lck shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved

chromophobe renal cell carcinoma

1 linked drug · 1 direct · 1 efficacy